Target intelligence / Profile preview

Fructooligosaccharides (FOS)

Target
FOS
Molecular classification
Carbohydrate, Prebiotic, Dietary fiber, Polysaccharide
01

Overview

Fructooligosaccharides (FOS) are short-chain fructose polymers linked by beta-(2,1) glycosidic bonds, which are resistant to human digestive enzymes. They are found naturally in various plants such as chicory, onions, and garlic, or produced commercially from sucrose or inulin. FOS function as prebiotics, selectively stimulating the growth and activity of beneficial colonic bacteria, particularly Bifidobacteria. This microbial fermentation leads to the production of short-chain fatty acids (SCFAs), which play a vital role in maintaining gut barrier integrity and systemic metabolic health. Clinically, FOS are used as dietary supplements to manage constipation, improve mineral absorption, and modulate the gut-immune axis. They are not considered traditional therapeutic targets (such as receptors or enzymes) but are instead bioactive molecules or pharmacological agents administered to influence the host's microbiome. While generally recognized as safe, high intake can lead to gastrointestinal distress, and they are frequently restricted in patients following low-FODMAP diets for irritable bowel syndrome.

Other names
OligofructoseOligofructanFructo-oligosaccharidesNeosugarProfeed
02

Mechanism of action

Fructooligosaccharides act as fermentable substrates that escape digestion in the upper gastrointestinal tract and reach the colon. There, they are selectively fermented by beneficial anaerobic bacteria, primarily Bifidobacterium and Lactobacillus species. This fermentation process produces short-chain fatty acids (SCFAs) like acetate, propionate, and butyrate, which lower luminal pH, inhibit the growth of pathogenic bacteria, and provide energy to colonocytes.

03

Biological functions

Selective stimulation of gut microbiota growthFermentation by colonic bacteriaShort-chain fatty acid (SCFA) productionEnhancement of mineral absorptionImmunomodulationRegulation of lipid metabolism
04

Disease associations

DysbiosisConstipationObesityType 2 diabetesInflammatory bowel diseaseIrritable bowel syndrome (as a FODMAP)Hypercholesterolemia
05

Safety considerations

Abdominal bloatingFlatulenceAbdominal crampingOsmotic diarrhea (at high doses)Exacerbation of symptoms in IBS patients (FODMAP sensitivity)
06

Interacting drugs

Bifidobacterium (as synbiotic)

3 more in the full profile.

07

Biomarkers

Fecal Bifidobacteria concentrationFecal pH levelFecal short-chain fatty acid (SCFA) levelsBreath hydrogen levels

Beyond the preview

Go deeper on Fructooligosaccharides (FOS).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fructooligosaccharides (FOS).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call